{"id":"NCT01004432","sponsor":"Janssen Biotech, Inc.","briefTitle":"Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)","officialTitle":"A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-12","primaryCompletion":"2013-07","completion":"2013-10","firstPosted":"2009-10-30","resultsPosted":"2014-05-13","lastUpdate":"2015-04-30"},"enrollment":433,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis","Arthritis, Rheumatoid","Autoimmune Diseases"],"interventions":[{"type":"DRUG","name":"Golimumab 50 mg SC","otherNames":[]},{"type":"DRUG","name":"Golimumab 2 mg/kg IV","otherNames":[]},{"type":"DRUG","name":"Methotrexate (MTX)","otherNames":[]},{"type":"DRUG","name":"Placebo SC","otherNames":[]},{"type":"DRUG","name":"Placebo IV","otherNames":[]}],"arms":[{"label":"Open-label (OL) Overall Group: Golimumab 50 mg SC + MTX","type":"EXPERIMENTAL"},{"label":"Double blind (DB) Group 2a: Golimumab 50mg SC & Placebo IV+MTX","type":"EXPERIMENTAL"},{"label":"DB Group 2b: Golimumab 2mg/kg IV & Placebo SC + MTX","type":"EXPERIMENTAL"},{"label":"OL Group 1: Golimumab 50 mg SC + MTX","type":"EXPERIMENTAL"},{"label":"OL Study Extension Group: Golimumab 50 mg SC + MTX","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of switching rheumatoid arthritis (RA) participants who have an inadequate response to their current treatment with either etanercept + methotrexate or adalimumab + methotrexate to treatment with golimumab 50 milligram (mg) subcutaneous (SC) injection (a needle inserted under the skin in the back of upper arm, upper thigh or stomach area) every 4 weeks + methotrexate. This study is also designed to evaluate the benefit and safety of switching participants from treatment with golimumab 50 mg subcutaneous injection every 4 weeks + methotrexate to golimumab 2 milligram per kilogram (mg/kg) intravenous every 8 weeks + methotrexate, for those who do not achieve a marked improvement of their RA at Week 16.","primaryOutcome":{"measure":"Percentage of Participants Achieving Erythrocyte Sedimentation Rate (ESR)-Based American College of Rheumatology [ACR] 20 Response at Week 14","timeFrame":"Week 14","effectByArm":[{"arm":"OL Overall Group: Golimumab 50 mg SC + MTX","deltaMin":34.9,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":117,"countries":["United States","Austria","Belgium","Canada","Germany","Greece","Sweden","United Kingdom"]},"refs":{"pmids":["29427176","28035867"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":433},"commonTop":["Upper respiratory tract infection","Urinary tract infection","Sinusitis","Arthralgia","Rheumatoid arthritis"]}}